By eHIV Review
5
33 ratings
The podcast currently has 58 episodes available.
Widespread use of highly effective ART has increased the life expectancy of people living with HIV (PLWH) to close to that of the general population. But despite highly effective viral suppression, the risks for cardiovascular diseases continue to increase in these individuals. So too do the risks of neurocognitive impairment.
Post-test for CME credits: https://elit.dkbmed.com/issues/206/test
Hosted on Acast. See acast.com/privacy for more information.
Current ART regimens can successfully manage HIV infection in nearly all PLWH. But what happens when a patient with HIV is coinfected with a dangerous pathogen ART alone cannot handle? Two of the most common are hepatitis B and latent tuberculosis infection.
Post-test for CME credits: https://elit.dkbmed.com/issues/203/test
Hosted on Acast. See acast.com/privacy for more information.
Pregnancy and menopause — for many women, these are two of the most significant healthcare events in their lives. For WLWH (women living with HIV) and their healthcare providers, managing these life-changing periods is often complicated by many questions.
Post-test for CME credits: https://elit.dkbmed.com/issues/201
Hosted on Acast. See acast.com/privacy for more information.
In part 1 of this eHIV Review Special Edition (still available at eHIVreview.org), eHIV Review Program Director Justin Alves, Nurse Educator at Boston Medical Center, reviewed the recent evidence describing some of the barriers to care experienced by marginalized individuals at risk for or living with HIV. In this Part 2 issue, he again calls upon two front-line clinicians in the fight to end the HIV epidemic in the U.S. — Nicky Mehtani, MD, from UCSF Medical Center in San Francisco, and Vanessa Loukas, NP, from Boston University’s Chobanian & Avedisian School of Medicine —to share their clinical approaches.
Post test for CME/CE credit: https://elit.dkbmed.com/issues/191/test
Hosted on Acast. See acast.com/privacy for more information.
Hosted on Acast. See acast.com/privacy for more information.
Hosted on Acast. See acast.com/privacy for more information.
A wealth of evidence confirms that adolescents and young adults (AYA) are indeed a priority population whose needs must be addressed for the US Ending the HIV Epidemic program to be successful. What do providers need to know about AYA to bring more of these patients into the HIV care continuum? What should they be doing? And what should they avoid doing?
Join us as guest author Dr. Vincent Guilamo-Ramos from the Duke University School of Nursing answers these and other questions, in this issue of eHIV Review.
Post test for CME/CE credit: https://elit.dkbmed.com/issues/183/test
Companion newsletter: https://elit.dkbmed.com/issues/182
Hosted on Acast. See acast.com/privacy for more information.
A wealth of evidence confirms that adolescents and young adults (AYA) are indeed a priority population whose needs must be addressed for the US Ending the HIV Epidemic program to be successful. What do providers need to know about AYA to bring more of these patients into the HIV care continuum? What should they be doing? And what should they avoid doing?
Join us as guest author Dr. Vincent Guilamo-Ramos from the Duke University School of Nursing answers these and other questions, in this issue of eHIV Review.
Post test for CME/CE credit: https://elit.dkbmed.com/issues/179/test
Companion newsletter: https://elit.dkbmed.com/issues/175
Hosted on Acast. See acast.com/privacy for more information.
Why do cisgender and transgender women, and particularly women of color, account for such a disproportionate percentage of HIV infections in the US? Why are so many so reluctant to accept PrEP? What can clinicians do to bridge this critical gap in essential HIV services?
These are some of the questions Guest Author Dr. Kathleen McManus, from the Division of Infectious Diseases and International Health at the University of Virginia, discusses in this issue of eHIV Review.
Take our post-test to claim CME credits.
Read this podcast's companion newsletter here.
Hosted on Acast. See acast.com/privacy for more information.
Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Rilpivirine, in combination with cabotegravir, provides a long-acting injectable option for both treatment and PrEP. But what risk factors have been associated with virologic failure? Doravirine appears to provide a favorable impact on weight and lipid outcomes, but with a lower genetic barrier to resistance. Which patients is it right for and in which ones should it be avoided?
Join us as we discuss Newer NNRTI Agents in Clinical Practice with Dr. Darcy Wooten from the Division of Infectious Disease at the University of California, San Diego, in this issue of eHIV Review.
Take our post-test to claim CME credits.
To read a companion newsletter click here.
Hosted on Acast. See acast.com/privacy for more information.
The podcast currently has 58 episodes available.